home / stock / akba / akba articles
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expecte...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply ...
HC Wainwright has upgraded Akebia Therapeutics Inc (NASDAQ: AKBA) from Neutral to Buy rating. Analysts Ed Arce ...
Covered a research piece on Akebia Therapeutics, a biopharmaceutical developing cutting-edge therapies for the treatment of patients with kidney diseases.
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...
2024-03-28 13:30:02 ET H.C. Wainwright analyst issues BUY recommendation for AKBA on March 28, 2024 12:08PM ET. The previous analyst recommendation was Buy. AKBA was trading at $2.0093 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...